Skip to content
The Policy VaultThe Policy Vault

Jadenu (deferasirox) — United Healthcare

Chronic iron overload in non-transfusion dependent thalassemia (NTDT) syndromes

Initial criteria

  • Diagnosis of chronic iron overload in non-transfusion dependent thalassemia (NTDT) syndrome
  • Patient has liver iron (Fe) concentration (LIC) levels consistently ≥ 5 mg Fe per gram of dry weight prior to initiation of treatment with Exjade or Jadenu
  • Patient has serum ferritin levels consistently > 300 mcg/L prior to initiation of treatment with Exjade or Jadenu

Reauthorization criteria

  • Documentation of positive clinical response to Exjade or Jadenu therapy

Approval duration

12 months